

REGISTERED NUMBER: 04426672 (England and Wales)

Abbreviated Unaudited Accounts for the Year Ended 30 April 2013

for

Blood Analysis Ltd

SATURDAY



A11 *A2IV29FS* 12/10/2013 #202
COMPANIES HOUSE

Blood Analysis Ltd

**Contents of the Abbreviated Accounts
for the Year Ended 30 April 2013**

	Page
Company Information	1
Abbreviated Balance Sheet	2
Notes to the Abbreviated Accounts	3

Blood Analysis Ltd

Company Information
for the Year Ended 30 April 2013

DIRECTORS: Mr P Salmon FCA
Mr A J Culverwell

SECRETARY: Mrs E L Salmon

REGISTERED OFFICE: The Old Stable
Farnham Lane
Farnham Royal
Slough
Berkshire
SL2 3SE

REGISTERED NUMBER: 04426672 (England and Wales)

Blood Analysis Ltd (Registered number 04426672)

Abbreviated Balance Sheet

30 April 2013

	Notes	30 4 13 £	30 4 12 £
CURRENT ASSETS			
Stocks		29,406	418,965
Debtors		7,263	36,690
Cash in hand		3,337	15,071
		<u>40,006</u>	<u>470,726</u>
CREDITORS			
Amounts falling due within one year		<u>2,482,594</u>	<u>2,153,554</u>
NET CURRENT LIABILITIES			
		<u>(2,442,588)</u>	<u>(1,682,828)</u>
TOTAL ASSETS LESS CURRENT LIABILITIES			
		<u>(2,442,588)</u>	<u>(1,682,828)</u>
CAPITAL AND RESERVES			
Called up share capital	2	53,877	53,877
Share premium		3,881,308	3,881,308
Profit and loss account		<u>(6,377,773)</u>	<u>(5,618,013)</u>
SHAREHOLDERS' FUNDS			
		<u>(2,442,588)</u>	<u>(1,682,828)</u>

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30 April 2013


The members have not required the company to obtain an audit of its financial statements for the year ended 30 April 2013 in accordance with Section 476 of the Companies Act 2006

The directors acknowledge their responsibilities for

- ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
- preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company

The abbreviated accounts have been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies

The financial statements were approved by the Board of Directors on 28 August 2013 and were signed on its behalf by



Mr P Salmon FCA - Director

The notes form part of these abbreviated accounts

Blood Analysis Ltd

Notes to the Abbreviated Accounts
for the Year Ended 30 April 2013

1 ACCOUNTING POLICIES

Accounting convention

The financial statements have been prepared under the historical cost convention

Financial reporting standard number 1

Exemption has been taken from preparing a cash flow statement on the grounds that the company qualifies as a small company

Turnover

Turnover represents net invoiced sales of services, excluding value added tax

Stocks

Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items

Deferred tax

Deferred tax is recognised on all timing differences where the transactions or events that give the company an obligation to pay more tax in the future, or a right to pay less tax in the future, have occurred by the balance sheet date. Deferred tax assets are recognised when it is more likely than not they will be recovered. Deferred tax is measured using rates of tax that have been enacted or substantively enacted by the balance sheet

No deferred tax asset has been recognised on the company's brought forward losses as the timing of future profit which would result in the realisation of asset associated with these losses is uncertain

Research and development

Expenditure on research and development is written off in the year in which it is incurred

Pension costs and other post-retirement benefits

The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to the profit and loss account in the period to which they relate

Going concern

The financial statements have been prepared on a going concern basis that BioCo Limited will provide financial support to the company for the foreseeable future until such time as income is earned each year from the sales of the Bac-Detect product

Financial instruments

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the entity after deducting all of its financial liabilities

Where the contractual terms of share capital do not have any terms meeting the definition of a financial liability then this is classed as an equity instrument

2 CALLED UP SHARE CAPITAL

Allotted, issued and fully paid

Number	Class	Nominal value	30 4 13	30 4 12
53,876,038	Ordinary	0 1p	<u>£ 53,877</u>	<u>£ 53,877</u>

Blood Analysis Ltd

Notes to the Abbreviated Accounts - continued
for the Year Ended 30 April 2013

3 ULTIMATE PARENT COMPANY

On 31 August 2006 the company was acquired by BioCo Limited, which is the immediate parent company

There is no ultimate controlling parent company however the director, Peter Salmon is the major shareholder